Biotechs are very much returning as investor favourites and the blue chip in the sector i.e. Novogen is looking great on the charts. The recent appointment of a "deal maker" to the board adds weight to arguements that we'll see a deal sooner rather than later.
Only a few weeks to see the full year result and then a few more till the AGM. Expect the AGM to start a buying spree in the stock.